See Our Current Investments

CLINICAL STUDIES

March 9th

NTI secures strategic Cultivation partnership to grow and maintain its medical cannabis
Neurotech expands exclusive license to include all neurological disorders

March 2nd 2021

Neurotech expands exclusive license to include all neurological disorders
Neurotech to commence clinical study program this quarter

February 15th 2021

Neurotech to commence clinical study program this quarter
NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await

December 21st 2020

NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await
OncoSil™ receives CE Mark approval

April 1st 2020

OncoSil™ receives CE Mark approval

Subscribe for updates on our small cap, ASX listed biotech portfolio.

Thanks for subscribing!

X